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Prophylactic anticoagulation in nephrotic
syndrome prevents thromboembolic
complications
Sarah Kelddal1,2* , Karen Marie Nykjær3, Jon Waarst Gregersen4 and Henrik Birn1,5
Abstract
Background: An increased incidence of thromboembolic events (TE) are reported in nephrotic syndrome (NS)
leading to recommendations for prophylactic anticoagulation (PAC). However, as no randomized clinical trial has
established the efficacy or risks associated with PAC, guidelines are empiric or substantiated only by estimates of
risks and benefits.
This study evaluates the risk of TE and hemorrhagic complications in patients with NS treated with PAC and
compares to patients not receiving PAC.
Methods: We included patients diagnosed with NS from two Danish nephrology departments with different
practices for the use of PAC. Patients were included if presenting with NS from September 2006 to January 2012, a
P-albumin < 30 g/L, and renal biopsy confirming non-diabetic, glomerular disease. Patients aged < 16 years, on renal
replacement therapy, or administered anticoagulants at the onset of NS were excluded. Bleeding episodes and/or
TE were identified from patient records. Bleeding episodes were divided into minor and major bleeding.
Results: Of the 79 patients included, 44 patients received PAC either as low or high dose low-molecular-weight
heparin (LMWH) or as warfarin with or without LMWH as bridging, while 35 did not receive PAC. P-albumin was
significant lower in the PAC group compared to those not receiving PAC. Significantly more TEs was observed in
the non-PAC group compared to the PAC group (4 versus 0 episodes, P = 0.035). The TEs observed included one
patient with pulmonary embolism (PE), one with PE and deep vein thrombosis, one with PE and renal vein
thrombosis, and one with a stroke. Five patients with bleeding episodes were identified among those receiving
PAC, of which two were major and three were minor, while two patients in the non-PAC group experienced a
minor bleeding episode (P = 0.45 between groups). The major bleeding episodes only occurred in patients
receiving PAC in combination with low dose aspirin.
Conclusions: In patients with NS the use of PAC was associated with a decreased risk of clinically significant TE, but
may also be associated with more bleeding episodes although not statistically significant. Only patients treated
with PAC in combination with anti-platelet therapy had major bleeding episodes.
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Background
Nephrotic syndrome (NS) is associated with an elevated
risk of thromboembolic events (TE) [1] leading to in-
creased morbidity and mortality [2, 3]. The incidence of
TE in NS has been estimated to 3–44% depending on
the localization of thrombosis and the extend of the
diagnostic screening [4, 5]. The risk of TE is greatest
within the first 3 months, although the risk remains ele-
vated for more than 5 years [1]. The pathophysiology
underlying the prothrombotic state is not well under-
stood. Several, essential hemostatic proteins, including
antithrombin III, and protein S, may be lost in the urine
because of the glomerular leakage associated to the pri-
mary glomerular defect [2]. Despite the urinary loss of
hemostatic proteins levels of some proteins, including fi-
brinogen, are increased and correlate with the hypoalbu-
minemia [6]. It is believed that hypoalbuminemia
stimulates the hepatic synthesis of hemostatic proteins
to make up for the urinary loss [7].
Membranous nephropathy is associated with the great-
est risk of TE at any level of serum albumin compared to
minimal change and focal segmental glomerulosclerosis
[8]. Other risk factors for venous TE include the severity
of NS at presentation, mail gender, increased ionized cal-
cium, and a decrease in plasma antithrombin III [2, 9]. A
low serum albumin level is also correlated with an in-
creased risk of TE and a previous study showed a 3-fold
increased risk of venous thromboembolic events when
serum albumin was below 2.5 g/dL [10]. Established risk
factors for arterial TE in NS include age, sex, hyperten-
sion, smoking, diabetes and low eGFR [11].
While the increased risk of TE in NS is well established,
there are no randomized studies to direct the use of
anti-coagulative therapy as primary prophylaxis. Only two
published trials have analyzed the effects of prophylactic antic-
oagulation (PAC) on TE in patients with NS. PAC was admin-
istered depending on serum albumin levels and the findings
suggested that the use of LMWH prevents TE, but no com-
parable control group were included in either of studies [12,
13]. Given the limited evidence international guidelines often
suggest PAC in selected patients with NS based on decision
analysis calculations of risk and benefits [14].
To further quantitate the potential benefits of PAC in
NS, this study investigated retrospectively the number
and type of TE as well as hemorrhagic complications in
a cohort of NS patients treated with PAC and compared
this to non-treated patients.
Methods
Design and inclusion
A retrospective analysis including incident and consecutive
patients diagnosed with NS and a renal biopsy confirming
glomerular disease from September 2006 to January 2012 at
two Danish Renal Departments. NS was defined as urinary
protein excretion greater than of 3.5 g/day and/or a urinary
albumin excretion greater than 2.2 g/day or 2200mg/g cre-
atinine in association with a plasma albumin < 30 g/L [15].
The follow up time were at least 3 weeks. Patients aged < 16
years, with diabetic kidney disease, on treatment with antico-
agulants at onset of NS, or on renal replacement therapy
were excluded. The study was approved by The Danish Na-
tional Board of Health and the Danish Data Protection
Agency. All data were anonymized prior to analyses and ac-
cording to Danish regulations, individual patient consent
was not required for this study.
Intervention
There were different practices regarding the use of PAC
in the two Renal Departments. At the Department of
Nephrology, Aarhus University Hospital all patients with
NS and plasma albumin < 20 g/L were treated with PAC
based on local guidelines recommending LMWH as the
initial treatment followed by warfarin at an INR target of
2–3 as oral maintenance therapy if required. The dosing
of LMWH and the monitoring of warfarin therapy was
at the discretion of the treating physician; however, bio-
chemical monitoring of LMWH by anti–factor Xa levels
was not common practice at the time of the study. In
contrast, PAC routinely used at the Department of In-
ternal Medicine, Viborg Regional Hospital irrespective of
plasma albumin levels.
PAC involved either warfarin alone, warfarin with bridg-
ing using low-molecular-weight heparin (LMWH), low
dose or high LMWH. Aspirin was not used as PAC, but pa-
tients treated with aspirin prior to the diagnosis of NS con-
tinued the treatment when initiated on LMWH and/or
warfarin. Aspirin was in general prescribed to prevent car-
diovascular disease; however, the exact indication in these
11 patients was not recorded.
Outcome
Baseline characteristics and outcomes were identified
from patient records. Baseline characteristics included
demographics, plasma albumin, eGFR, urine protein
and/or protein, date of renal biopsy and histological
diagnosis. P-creatinine, U-creatinine, P-albumin and
U-albumin were all measured using automated, stan-
dardized clinical assays. All diagnoses of TE and/or
bleeding episodes during follow-up were identified
from patient records. The diagnosis and workup for a
TE was instigated by clinical suspicion as no system-
atic screening for TE was performed. The TE identi-
fied included pulmonary embolism (PE), deep vein
thrombosis (DVT), renal vein thrombosis (RVT), and
stroke. Bleeding episodes were divided into major
bleedings or minor bleedings based on whether blood
transfusion was required or not.
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Data analysis
Baseline demographics and outcomes were compared using
Fisher’s exact test for categorical measures and Mann Whit-
ney U-test for continuous variables. Data were described
using range or medians [interquartile range (IQR)] and a
two-sided p-value < 0.05 is considered statistically significant.
Results
A total of 79 patients presenting with NS due to glomeru-
lar disease were included in the study. Forty-four patients
received PAC and 35 did not. Based on biopsy findings, 35
patients were diagnosed with minimal change disease, 19
were diagnosed with membranous nephropathy, 7 were
diagnosed with focal segmental glomerulosclerosis and 18
were diagnosed with other causes such as amyloidosis or
non-specific glomerular disease. No significant differences
were identified between groups in terms of gender, age
and renal function at baseline (Table 1); however,
plasma-albumin was significantly lower in the in the PAC
group compared to the non-PAC group, (15 g/L, range
10–23 g/L, vs. 20 g/L, range, 11–29 g/L, p < 0.001.
The PAC regimes varied among patients and included
patients receiving warfarin with or without bridging as
well as LMWH using variable dosing regimens (Table 2).
Only two patients from Viborg Regional Hospital re-
ceived anticoagulation treatment (plasma albumin levels
16 g/L and 23 g/l, respectively). Eleven patients received
anti-platelet therapy and four patients received both
anti-platelet therapy and PAC.
None of the 44 patients receiving PAC experienced a
clinical TE while four patients (11%) had a diagnosis of
TE among the 35 patients not receiving PAC (P = 0.035,
Fischer’s exact test) (Table 3).
The majority of thromboembolic episodes occurred
within the first month after the diagnosis of nephrotic syn-
drome, and included one patient with PE, one patient with
PE and DVT, one patient with PE and RVT, and one pa-
tient with a stroke (Fig. 1). The glomerular pathology ob-
served in the four patients experiencing a TE was
membranous glomerulopathy (n = 2), glomerulosclerosis
(n = 1), and vasculitis (n = 1). Five bleeding episodes (11%)
were recorded among patients receiving PAC, including
two major episodes of gastrointestinal bleeding, of which
one was fatal, and three minor. Two minor bleeding epi-
sodes were recorded among patients not receiving PAC.
This difference was not statistically significant (P= 0.45,
Fischer’s exact test). Notably, the two major bleeding epi-
sodes were observed in patients on warfarin in combination
with low dose aspirin. Two of three patients on PAC having
a minor bleeding episode were on warfarin and the INR was
above target at the time of bleeding (4.5 and 6.7, respectively)
while one patient was receiving low dose LMWH.
Discussion
Based on a retrospective analysis this study shows that the
use of PAC to all patients with NS and a P-albumin < 2.0 g/
dL significantly reduced the number of clinically significant
TE. It was also associated with a non-significant increase in
the number of bleeding episodes of which one was fatal.
We are able to compare the PAC-treated NS patients to
a group of untreated patients as there were different prac-
tices regarding the use of PAC in the two neighboring,
renal departments. The two groups were comparable re-
garding gender, age or renal function; however, plasma al-
bumin was significantly lower in the PAC-group. Different
studies have shown that hypoalbuminemia is a major risk
factor and strongly associated with venous TE, [9, 16] and
thus is possible that the non-treated group was biased
against a lower risk of TE suggesting that benefit of PAC
in preventing TE may be greater than observed. The inci-
dence of TE in our study, including both arterial and ven-
ous thromboembolic events, was 12%. Like previous
studies [1] we also found most TE to occur within the first
months after the diagnosis of NS.
A total of seven patients experienced a bleeding epi-
sode of which five were receiving PAC. Two of these pa-
tients had major gastrointestinal bleedings, which
required blood transfusion. Both these patients received
warfarin in combination with low dose aspirin but un-
fortunately INR was not recorded at the onset of the
bleeding episodes. One of these patients developed cir-
culatory failure and eventually died. Three patients in
Table 1 Baseline data
Demographics Anticoagulation Non-anticoagulation p-value
Number 44 35
Male, n (%) 26 (59) 13 (37) 0.053
Median age (year, range) 43 (17–78) 52 (22–84)
Median serum creatinine (μmol/L, range) 83 (37–547) 107 (43–208)
Plasma albumin (g/L, range) 15 (10–23) 20 (11–29) < 0.001
Duration of treatment (days) 26 (1–350) – –
Follow-up time (weeks, IQR) 92 (34–178) 49 (19–98) 0.19
Data represent number, range (minimum and maximum value; IQR). Comparison between PAC and non-PAC was made using, Fischer’s test or Mann
Whitney U-test
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the PAC group experienced a minor bleeding episode
with minor hematomas or a small bleeding in the eyelid.
At the time of bleeding, two of the three patients were
receiving warfarin with an INR above target range (4.5
and 6.7 respectively). Thus, it is possible that some of
these bleeding episodes may be preventable if combina-
tions with aspirin were avoided and a more rigorous
control of INR was instituted.
Only two previous studies have examined the association
between nephrotic syndrome, thromboembolic events and
PAC. In a study including 143 NS patients receiving either
Enoxaparin or low dose of aspirin depending on serum-albu-
min, two cases of PE were identified during the first week of
treatment; However, it was not clear if the TE actually hap-
pened before the start of PAC. Seven patients were reported
to have gastrointestinal bleeding episodes of which five were
receiving aspirin and two were on Enoxaparin [12]. A smaller
study evaluated 55 patients with NS and a median serum al-
bumin of 17 g/l receiving Enoxaparin 40 IE until urine protein
excretion was below 3 g/day [13]. No thromboembolic events
were identified and only one episode of menorrhagia was re-
ported [13]. Similar to our study both studies observed bleed-
ing episodes in patients receiving PAC, in particular in
relation to aspirin. In contrast to our study, none of these
studies included a comparison group, and thus it is not pos-
sible to assess if PAC was successful in preventing TE, al-
though the number of observed TE appears to be low
compared to the reported incidences in other studies.
Our study is limited by the small study sample size, the
retrospective design and the inclusion of only clinically re-
ported TE and bleeding episodes which may underestimate
the frequency of both smaller bleeding episodes and subclin-
ical TE. Furthermore, although not significant male sex, a
risk factor for TE, tended to be more frequent in the group
receiving PAC. This may lead to an underestimation of the
preventive effect of PAC when comparing to the group not
receiving PAC. In addition, the allocation to PAC were based
on different practices in two different nephrology depart-
ments implying that other differences in practices may affect
the outcome. Furthermore, no algorithm for the selection
between Warfarin, LMWH or aspirin was applied. However,
except for plasma albumin levels the groups were similar
and recruited within the same region of Denmark. Inclusion
was based strictly on biochemical criteria and biopsy proven
glomerular disease. Given the limited available evidence we
believe that the findings provide relevant information to
guide PAC in NS.
International guidelines recommend full-dose anticoa-
gulation with LMWH or Warfarin should be considered
if serum albumin is below 20–25 g/L in combination
with one or more risk factors [17]. Given our findings it
is likely that this may prevent TE; however, at the pos-
sible costs of increased risk of major and potential fatal
bleeding episodes. Thus, careful attention to other fac-
tors implying bleeding risks may be recommend and the
combination with platelet inhibitors should be avoided.
Table 2 Intervention
Intervention (PAC) Anticoagulation Non-anticoagulation p-value
Number 44 35
PAC treatment: (At initial presentation)
Low dose LMWH, n (%)a 15 (34) – –
High dose LMWH, n (%)b 7 (16) – –
Warfarin with LMWH bridging, n (%)c 16 (36) – –
Warfarin without bridging, n (%) 6 (13)
Anti-platelet treatmentd, n (%) 4 (9) 7 (20) 0.20
Range: Minimum and maximum value; IQR: inter quartile range
aDalteparin ≤5.000 IE/day or Enoxaparin 40 IE/day
bDalteparin ≥7.500 IE/day or Enoxaparin 80 IE
cWarfarin in combination with Dalteparin or Enoxaparin in any dose
dAspirin 75 mg daily
Table 3 Thromboembolic events and bleeding episodes
TE and bleeding episodes Anticoagulation Non-anticoagulation p-value
Number 44 35
Time to TE, (days, IQR) 22 (7–220)
Thromboembolic events (TE), n (%) 0 (0) 4 (12) 0.035
Bleeding episodes, n (%) 5 (11) 2 (6) 0.45
Major, n (%) 2 (5) 0 (0) 0.50
Minor, n (%) 3 (7) 2 (6) 1.00
Major bleeding was only observed in patients on concomitant PAC and anti-platelet treatment
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Conclusions
This retrospective analysis showed that PAC treatment
was associated with a decreased risk of clinically signifi-
cant TE in patients with NS, but may also be associated
with more bleeding episodes, although this difference
was not statistically significant between groups. Major
bleeding episodes were only observed in patients on
concomitant anti-platelet therapy.
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